Biotech comeback: Eli Lilly making renewed push in lucrative field it once pioneered
Lilly expects to soon announce late-stage clinical trial results for two biotech drugs designed to slow the inflammation caused by autoimmune diseases. By the end of the year, it will announce results for a third.